Vaccines with limited ability to prevent HIV infection may positively impact the HIV/AIDS pandemic by preventing secondary transmission and disease in vaccine recipients who become infected. To evaluate the impact of vaccination on secondary transmission and disease, efficacy trials assess vaccine effects on HIV viral load and other surrogate endpoints measured after infection. A standard test that compares the distribution of viral load between the infected subgroups of vaccine and placebo recipients does not assess a causal effect of vaccine, because the comparison groups are selected after randomization. To address this problem, we formulate clinically relevant causal estimands using the principal stratification framework developed by F...
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of random...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
SUMMARY. In many experiments researchers would like to compare between treatments an outcome that on...
Thesis (Ph. D.)--University of Washington, 2005.In many experiments researchers would like to compar...
The effects of vaccine on postinfection outcomes, such as disease, death, and secondary transmission...
The effects of vaccine on postinfection outcomes, such as disease, death, and secondary transmission...
Infectious disease prevention studies often aim to test or estimate the "causal effect" of a prevent...
In some clinical trials, the primary outcome of interest may only be measured in a subset of subject...
Establishing statistical methods for quantifying the effects of interventions to prevent infectious ...
This article introduces methods for use in vaccine clinical trials to help determine whether the imm...
Many HIV vaccine trials have been proposed to evaluate susceptibility of individuals. However, vac c...
We examine the structural bias for established estimators of vaccine effects on susceptibility and f...
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of random...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of random...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
SUMMARY. In many experiments researchers would like to compare between treatments an outcome that on...
Thesis (Ph. D.)--University of Washington, 2005.In many experiments researchers would like to compar...
The effects of vaccine on postinfection outcomes, such as disease, death, and secondary transmission...
The effects of vaccine on postinfection outcomes, such as disease, death, and secondary transmission...
Infectious disease prevention studies often aim to test or estimate the "causal effect" of a prevent...
In some clinical trials, the primary outcome of interest may only be measured in a subset of subject...
Establishing statistical methods for quantifying the effects of interventions to prevent infectious ...
This article introduces methods for use in vaccine clinical trials to help determine whether the imm...
Many HIV vaccine trials have been proposed to evaluate susceptibility of individuals. However, vac c...
We examine the structural bias for established estimators of vaccine effects on susceptibility and f...
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of random...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
Assessing per-protocol treatment effcacy on a time-to-event endpoint is a common objective of random...
If a vaccine does not protect individuals completely against infection, it could still reduce infect...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...